David P. Southwell

Biography

Mr. Southwell joined Inotek in August 2014 as President and Chief Executive Officer. Mr. Southwell conveys to Inotek more than 20 years of claim to fame pharmaceuticals and biotechnology encounter, including IPOs, take after on financings, mergers and acquisitions and corporate initiative. Most as of late, Mr. Southwell filled in as Executive Vice President and Chief Financial Officer of Human Genome Sciences amid the endorsement and dispatch of the novel biologic treatment for lupus, Benlysta®, and up until its obtaining by Glaxo Smithkline. Before his arrangement as CFO, he served on the Board of Directors of Human Genome Sciences. Mr. Southwell's profession begun in venture managing an account at Lehman Brothers, where among other financing and M&A exchanges he drove the IPO of Sepracor Inc. He along these lines joined Sepracor as EVP, Chief Financial Officer, a position he held for a long time amid which time Sepracor brought over $2 billion up in value and convertible security financings, and created, propelled and marketed two novel drugs for asthma and sleep deprivation. Following his opportunity at Sepracor, he mounted a subsidized take-private offer for the organization with the organization's organizer, which prompted its obtaining by Dainippon Sumitomo in 2009. Mr. Southwell serves on the sheets of PTC Therapeutics and on the Board of Overseers of the Tuck School of Business at Dartmouth College. His past board participations incorporate Biosphere Medical, Inc. (gained) as Chairman, InVentiv Health, and THL Credit, Inc. He holds a MBA from the Tuck School, and a BA is from Rice University. 

Research Interest

Trabodenoson, Fixed Dose Combination, Neuroprotection